The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.
|Videos|February 16, 2016
- Head and Neck Cancers (Issue 4)
- Volume 3
- Issue 4
Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid Cancer
Author(s)Ramona Dadu, MD
Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.
Advertisement
Ramona Dadu, MD, endocrinologist, MD Anderson Cancer Center, discusses the benefits of using immunotherapies in thyroid cancer and some of the potential drawbacks that coincide with the treatments. Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.
Articles in this issue
over 10 years ago
Immunotherapies Gaining Traction in Head and Neck Cancersover 10 years ago
Dr. Sylvia Asa on Treating Different Types of Thyroid Cancerover 10 years ago
Link Drawn Between Oral HPV and Risk of Head and Neck Cancersover 10 years ago
Nivolumab Could Change Head and Neck Cancer Treatment Paradigmover 10 years ago
Nivolumab Boosts OS in Phase III in SCCHN StudyAdvertisement
Related to this article
Personalized ctDNA monitoring guides adjuvant therapy and flags head and neck cancer relapse months early, showing high sensitivity across HPV subtypes.
FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, manufacturing controls, lot release assays, and monitoring.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5